These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 6282967

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T, Anam K, Ali N.
    Vaccine; 2004 Mar 12; 22(9-10):1162-71. PubMed ID: 15003644
    [Abstract] [Full Text] [Related]

  • 25. Treatment of experimental visceral leishmaniasis with lymphokine encapsulated in liposomes.
    Reed SG, Barral-Netto M, Inverso JA.
    J Immunol; 1984 Jun 12; 132(6):3116-9. PubMed ID: 6725947
    [Abstract] [Full Text] [Related]

  • 26. An experimental model system for leishmaniasis. An ultrastructural study on cultured macrophages exposed to Leishmania parasites and sodium stibogluconate.
    Abok K, Fredriksson BA, Brunk U.
    APMIS; 1988 Jul 12; 96(7):589-95. PubMed ID: 2841954
    [Abstract] [Full Text] [Related]

  • 27. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice.
    Dey R, Majumder N, Bhattacharyya Majumdar S, Bhattacharjee S, Banerjee S, Roy S, Majumdar S.
    Scand J Immunol; 2007 Dec 12; 66(6):671-83. PubMed ID: 18021365
    [Abstract] [Full Text] [Related]

  • 28. Presentation of the protective parasite antigen LACK by Leishmania-infected macrophages.
    Prina E, Lang T, Glaichenhaus N, Antoine JC.
    J Immunol; 1996 Jun 01; 156(11):4318-27. PubMed ID: 8666803
    [Abstract] [Full Text] [Related]

  • 29. Pretreatment with phorbol myristate acetate inhibits macrophage activity against intracellular protozoa.
    Murray HW.
    J Reticuloendothel Soc; 1982 Jun 01; 31(6):479-87. PubMed ID: 6288939
    [Abstract] [Full Text] [Related]

  • 30. Visceral leishmaniasis: a disease associated with inability of lymphocytes to activate macrophages to kill leishmania.
    Carvalho EM, Bacellar OA, Reed S, Barral A, Rocha H.
    Braz J Med Biol Res; 1988 Jun 01; 21(1):85-92. PubMed ID: 3179584
    [Abstract] [Full Text] [Related]

  • 31. Studies on the mechanisms of macrophage activation: possible involvement of oxygen metabolites in killing of Leishmania enrietti by activated mouse macrophages.
    Buchmüller Y, Mauel J.
    J Reticuloendothel Soc; 1981 Mar 01; 29(3):181-92. PubMed ID: 6260943
    [No Abstract] [Full Text] [Related]

  • 32. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.
    Samant M, Gupta R, Kumari S, Misra P, Khare P, Kushawaha PK, Sahasrabuddhe AA, Dube A.
    J Immunol; 2009 Jul 01; 183(1):470-9. PubMed ID: 19542458
    [Abstract] [Full Text] [Related]

  • 33. Signaling events leading to the curative effect of cystatin on experimental visceral leishmaniasis: involvement of ERK1/2, NF-kappaB and JAK/STAT pathways.
    Kar S, Ukil A, Das PK.
    Eur J Immunol; 2009 Mar 01; 39(3):741-51. PubMed ID: 19197936
    [Abstract] [Full Text] [Related]

  • 34. An experimental model system for leishmaniasis. Effects of porphyrin-compounds and menadione on Leishmania parasites engulfed by cultured macrophages.
    Abok K, Cadenas E, Brunk U.
    APMIS; 1988 Jun 01; 96(6):543-51. PubMed ID: 3395481
    [Abstract] [Full Text] [Related]

  • 35. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
    Sharma SK, Dube A, Nadeem A, Khan S, Saleem I, Garg R, Mohammad O.
    Vaccine; 2006 Mar 10; 24(11):1800-10. PubMed ID: 16310900
    [Abstract] [Full Text] [Related]

  • 36. Relationship between parasite load and immune responses in early stages of Leishmania donovani infection in inbred BALB/c mice.
    Wahinya DN, Mbati PA, Jomo PM, Githure JI.
    East Afr Med J; 1998 Mar 10; 75(3):156-9. PubMed ID: 9640813
    [Abstract] [Full Text] [Related]

  • 37. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
    Tripathi P, Gupta SK, Sinha S, Sundar S, Dube A, Naik S.
    Scand J Immunol; 2008 Nov 10; 68(5):492-501. PubMed ID: 18803606
    [Abstract] [Full Text] [Related]

  • 38. Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines.
    Sarkar K, Das PK.
    J Immunol; 1997 Jun 01; 158(11):5357-65. PubMed ID: 9164956
    [Abstract] [Full Text] [Related]

  • 39. DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection.
    Carter KC, Henriquez FL, Campbell SA, Roberts CW, Nok A, Mullen AB, McFarlane E.
    Vaccine; 2007 May 30; 25(22):4502-9. PubMed ID: 17418459
    [Abstract] [Full Text] [Related]

  • 40. Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis.
    Narayan S, Bimal S, Singh SK, Gupta AK, Singh VP, Sinha PK, Das P.
    Exp Parasitol; 2009 Jan 30; 121(1):69-75. PubMed ID: 18948098
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.